NasdaqGS:KLDO

Stock Analysis Report

Executive Summary

Kaleido BioSciences, Inc. develops microbiome metabolic therapies.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Risks

  • Kaleido BioSciences has significant price volatility in the past 3 months.

Share Price & News

How has Kaleido BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.1%

NasdaqGS:KLDO

-0.07%

US Pharmaceuticals

0.8%

US Market


1 Year Return

n/a

NasdaqGS:KLDO

-9.4%

US Pharmaceuticals

1.9%

US Market

No trading data on KLDO.

No trading data on KLDO.


Share holder returns

KLDOIndustryMarket
7 Day-3.1%-0.07%0.8%
30 Day0.8%0.4%3.4%
90 Day-31.1%-5.8%2.1%
1 Yearn/a-7.2%-9.4%4.2%1.9%
3 Yearn/a12.3%4.4%46.7%37.2%
5 Yearn/a20.8%7.9%62.3%44.5%

Price Volatility Vs. Market

How volatile is Kaleido BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kaleido BioSciences undervalued based on future cash flows and its price relative to the stock market?

3.17x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Kaleido BioSciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Kaleido BioSciences to establish if it is available at substantial discount.


Price Based on Earnings

Kaleido BioSciences is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Kaleido BioSciences is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Kaleido BioSciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Kaleido BioSciences is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Kaleido BioSciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

-3.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Kaleido BioSciences is high growth as no revenue estimate data is available.

Kaleido BioSciences is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Kaleido BioSciences's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Kaleido BioSciences's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Kaleido BioSciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Kaleido BioSciences will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Kaleido BioSciences performed over the past 5 years?

-108.1%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Kaleido BioSciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Kaleido BioSciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Kaleido BioSciences's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Kaleido BioSciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Kaleido BioSciences has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Kaleido BioSciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Kaleido BioSciences's financial position?


Financial Position Analysis

Kaleido BioSciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Kaleido BioSciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Kaleido BioSciences's level of debt (17.6%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Kaleido BioSciences's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 6.8x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Kaleido BioSciences has sufficient cash runway for 1.4 years based on current free cash flow.

Kaleido BioSciences has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 62.3% each year.


Next Steps

Dividend

What is Kaleido BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Kaleido BioSciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Kaleido BioSciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Kaleido BioSciences has not reported any payouts.

Unable to verify if Kaleido BioSciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Kaleido BioSciences has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Kaleido BioSciences's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Kaleido BioSciences's salary, the management and board of directors tenure and is there insider trading?

1.1yrs

Average management tenure


CEO

Alison Lawton (58yo)

1.1yrs

Tenure

US$6,644,129

Compensation

Ms. Alison Lawton has been the Chief Executive Officer and Director of Kaleido BioSciences, Inc. since August 2018 and has been its President since December 2017. Ms. Lawton initially joined the Kaleido Bi ...


CEO Compensation Analysis

Alison's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Alison to compare compensation growth.


Management Age and Tenure

1.1yrs

Average Tenure

54yo

Average Age

The average tenure for the Kaleido BioSciences management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.8yrs

Average Tenure

57.5yo

Average Age

The average tenure for the Kaleido BioSciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$13,999,99506 Mar 19
Flagship Pioneering
EntityCompany
Shares933,333
Max PriceUS$15.00
BuyUS$999,49305 Mar 19
Michael Bonney
EntityIndividual
Role
Chairman of the Board
Executive Chair
Shares71,520
Max PriceUS$14.65

Ownership Breakdown


Management Team

  • Mike Bonney (61yo)

    Executive Chair

    • Tenure: 0yrs
    • Compensation: US$9.92m
  • Alison Lawton (58yo)

    CEO, President & Director

    • Tenure: 1.1yrs
    • Compensation: US$6.64m
  • Geoff von Maltzahn (38yo)

    Co-Founder & Director

    • Tenure: 0yrs
  • Josh Brumm (41yo)

    COO & CFO

    • Tenure: 1.4yrs
    • Compensation: US$2.95m
  • Wendy Arnold

    Senior Vice President of Human Resources

    • Tenure: 1.7yrs
  • Michael Bruce (49yo)

    Senior Vice President of Development Operations

    • Tenure: 1.1yrs
  • Johan Hylckama Vlieg

    Chief Scientific Officer

    • Tenure: 0.2yrs
  • Katharine Knobil (54yo)

    Chief Medical Officer and Head of Research & Development

    • Tenure: 0.8yrs
    • Compensation: US$4.14m
  • John Davies (58yo)

    Chief Technology Officer

    • Tenure: 1.9yrs
  • Jerald Korn

    General Counsel & Corporate Secretary

    • Tenure: 0.2yrs

Board Members

  • John Sculley (79yo)

    Director

    • Tenure: 0.8yrs
  • Mike Bonney (61yo)

    Executive Chair

    • Tenure: 0yrs
    • Compensation: US$9.92m
  • Theo Melas-Kyriazi (60yo)

    Director

    • Tenure: 0.2yrs
  • Laurie Glimcher (67yo)

    Member of Scientific Advisory Board

    • Tenure: 0.7yrs
  • Alison Lawton (58yo)

    CEO, President & Director

    • Tenure: 1.1yrs
    • Compensation: US$6.64m
  • Jonathan McIntyre (55yo)

    Director

    • Tenure: 0yrs
  • Bonnie Bassler (57yo)

    Director

    • Tenure: 0.8yrs
  • Grady Burnett (45yo)

    Director

    • Tenure: 1yrs
  • Anthony Quinn (57yo)

    Director

    • Tenure: 3.6yrs
  • Geoff von Maltzahn (38yo)

    Co-Founder & Director

    • Tenure: 0yrs

Company Information

Kaleido BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kaleido BioSciences, Inc.
  • Ticker: KLDO
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$268.710m
  • Shares outstanding: 29.79m
  • Website: https://www.kaleido.com

Number of Employees


Location

  • Kaleido BioSciences, Inc.
  • 65 Hayden Avenue
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KLDONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2019

Biography

Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infectio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 01:41
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.